USD 57.38
(-4.95%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 41.87 Million USD | 97.26% |
2022 | -386.73 Million USD | 35.16% |
2021 | -617.72 Million USD | -59.26% |
2020 | -632.85 Million USD | -113.53% |
2019 | -217.74 Million USD | -36.54% |
2018 | -115.18 Million USD | -34.79% |
2017 | -98.82 Million USD | 30.0% |
2016 | -155.48 Million USD | -6.25% |
2015 | -150.04 Million USD | -58.22% |
2014 | -96.28 Million USD | -116.47% |
2013 | -45.02 Million USD | 11.33% |
2012 | -51.39 Million USD | -84.36% |
2011 | -28.25 Million USD | -139.97% |
2010 | -11.32 Million USD | -28.5% |
2009 | -9.07 Million USD | -13.15% |
2008 | -8.74 Million USD | 22.4% |
2007 | -12.84 Million USD | 18.18% |
2006 | -14.16 Million USD | 10.83% |
2005 | -15.63 Million USD | 25.07% |
2004 | -19.19 Million USD | 33.44% |
2003 | -28.83 Million USD | -0.53% |
2002 | -28.68 Million USD | -14.37% |
2001 | -25.13 Million USD | -282.49% |
2000 | -9.74 Million USD | -35.52% |
1999 | -4.83 Million USD | -20.33% |
1998 | -4.02 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -48.3 Million USD | -499.07% |
2024 Q2 | 31.09 Million USD | 174.92% |
2024 Q3 | 3.1 Million USD | -24.62% |
2023 FY | - USD | 97.26% |
2023 Q4 | -14.99 Million USD | -150.26% |
2023 Q1 | -54.51 Million USD | 41.09% |
2023 Q2 | -53.44 Million USD | 1.96% |
2023 Q3 | 29.84 Million USD | 155.83% |
2022 Q2 | -102.56 Million USD | 21.56% |
2022 Q4 | -92.53 Million USD | -8.88% |
2022 FY | - USD | 35.16% |
2022 Q1 | -130.75 Million USD | 33.76% |
2022 Q3 | -84.98 Million USD | 17.13% |
2021 FY | - USD | -59.26% |
2021 Q1 | -256.84 Million USD | 34.5% |
2021 Q2 | -127.76 Million USD | 50.25% |
2021 Q3 | -97.05 Million USD | 24.04% |
2021 Q4 | -197.4 Million USD | -103.39% |
2020 Q3 | 48.35 Million USD | 210.95% |
2020 FY | - USD | -113.53% |
2020 Q4 | -392.1 Million USD | -910.95% |
2020 Q2 | -43.57 Million USD | 0.62% |
2020 Q1 | -43.85 Million USD | 46.74% |
2019 FY | - USD | -36.54% |
2019 Q4 | -82.32 Million USD | -210.7% |
2019 Q3 | -26.49 Million USD | 21.65% |
2019 Q1 | -68.19 Million USD | -38.28% |
2019 Q2 | -33.82 Million USD | 50.41% |
2018 Q2 | -27.55 Million USD | 24.55% |
2018 Q1 | -36.52 Million USD | -57.91% |
2018 Q3 | -34.76 Million USD | -26.15% |
2018 Q4 | -49.31 Million USD | -41.86% |
2018 FY | - USD | -34.79% |
2017 Q1 | -32.24 Million USD | 14.5% |
2017 FY | - USD | 30.0% |
2017 Q4 | -23.13 Million USD | 4.83% |
2017 Q3 | -24.3 Million USD | 12.16% |
2017 Q2 | -27.67 Million USD | 14.18% |
2016 Q2 | -42.71 Million USD | 5.87% |
2016 Q3 | -35.85 Million USD | 16.06% |
2016 Q1 | -45.37 Million USD | -12.27% |
2016 FY | - USD | -6.25% |
2016 Q4 | -37.71 Million USD | -5.17% |
2015 Q3 | -43.63 Million USD | -10.3% |
2015 Q4 | -40.42 Million USD | 7.37% |
2015 Q2 | -39.55 Million USD | -14.86% |
2015 Q1 | -34.44 Million USD | -5.71% |
2015 FY | - USD | -58.22% |
2014 Q1 | -16.09 Million USD | -32.23% |
2014 FY | - USD | -116.47% |
2014 Q4 | -32.58 Million USD | -1.16% |
2014 Q3 | -32.2 Million USD | -65.82% |
2014 Q2 | -19.42 Million USD | -20.71% |
2013 Q2 | -12.35 Million USD | -13.99% |
2013 Q3 | -11.24 Million USD | 8.94% |
2013 Q1 | -10.83 Million USD | 22.43% |
2013 Q4 | -12.17 Million USD | -8.21% |
2013 FY | - USD | 11.33% |
2012 Q3 | -13 Million USD | 12.64% |
2012 FY | - USD | -84.36% |
2012 Q2 | -14.89 Million USD | -39.13% |
2012 Q4 | -13.96 Million USD | -7.38% |
2012 Q1 | -10.7 Million USD | -9.35% |
2011 Q3 | -7.72 Million USD | -17.7% |
2011 FY | - USD | -139.97% |
2011 Q2 | -6.56 Million USD | -51.42% |
2011 Q1 | -4.33 Million USD | -8.27% |
2011 Q4 | -9.78 Million USD | -26.68% |
2010 Q1 | -2.12 Million USD | -16.71% |
2010 Q3 | -3.39 Million USD | -39.93% |
2010 Q4 | -4 Million USD | -17.9% |
2010 FY | - USD | -28.5% |
2010 Q2 | -2.42 Million USD | -14.32% |
2009 Q3 | -1.05 Million USD | 56.44% |
2009 FY | - USD | -13.15% |
2009 Q4 | -1.81 Million USD | -71.93% |
2009 Q2 | -2.42 Million USD | 35.6% |
2009 Q1 | -3.77 Million USD | -104.44% |
2008 Q3 | -1.23 Million USD | 34.48% |
2008 Q4 | -1.84 Million USD | -49.64% |
2008 FY | - USD | 22.4% |
2008 Q1 | -2.64 Million USD | 24.05% |
2008 Q2 | -1.88 Million USD | 28.87% |
2007 Q4 | -3.48 Million USD | -23.15% |
2007 FY | - USD | 18.18% |
2007 Q1 | -2.11 Million USD | -2.92% |
2007 Q2 | -2.06 Million USD | 2.18% |
2007 Q3 | -2.82 Million USD | -36.87% |
2006 Q4 | -2.05 Million USD | 39.67% |
2006 FY | - USD | 10.83% |
2006 Q1 | -4.48 Million USD | -48.77% |
2006 Q2 | -3.55 Million USD | 20.58% |
2006 Q3 | -3.4 Million USD | 4.38% |
2005 Q4 | -3.01 Million USD | 15.84% |
2005 FY | - USD | 25.07% |
2005 Q3 | -3.57 Million USD | 15.03% |
2005 Q2 | -4.21 Million USD | -17.69% |
2005 Q1 | -3.57 Million USD | 24.73% |
2004 Q1 | -5.4 Million USD | 6.95% |
2004 Q2 | -4.45 Million USD | 17.71% |
2004 Q4 | -4.75 Million USD | -3.82% |
2004 Q3 | -4.58 Million USD | -2.9% |
2004 FY | - USD | 33.44% |
2003 Q1 | -7.87 Million USD | -29.62% |
2003 FY | - USD | -0.53% |
2003 Q2 | -7.65 Million USD | 2.73% |
2003 Q3 | -6.96 Million USD | 9.01% |
2003 Q4 | 22.54 Million USD | 16.54% |
2002 Q1 | -7.41 Million USD | -9.56% |
2002 Q4 | -6.07 Million USD | 18.83% |
2002 Q2 | -7.72 Million USD | -4.22% |
2002 FY | - USD | -14.37% |
2002 Q3 | -7.47 Million USD | 3.17% |
2001 Q2 | -6.29 Million USD | -5.17% |
2001 Q4 | -6.76 Million USD | -12.24% |
2001 Q1 | -5.99 Million USD | 0.0% |
2001 FY | - USD | -282.49% |
2001 Q3 | -6.02 Million USD | 4.32% |
2000 FY | - USD | -35.52% |
1999 FY | - USD | -20.33% |
1998 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Bionano Genomics, Inc. | -213.6 Million USD | 119.605% |
Prenetics Global Limited | -47.89 Million USD | 187.431% |
Star Equity Holdings, Inc. | -1.68 Million USD | 2582.276% |
CareDx, Inc | -89.65 Million USD | 146.707% |
Exagen Inc. | -19.15 Million USD | 318.639% |
Inotiv, Inc. | -26.5 Million USD | 257.987% |
Guardant Health, Inc. | -433.3 Million USD | 109.664% |
Biodesix, Inc. | -37.1 Million USD | 212.864% |
BioNexus Gene Lab Corp. | -2.48 Million USD | 1785.042% |
Precipio, Inc. | -4.31 Million USD | 1069.801% |
iSpecimen Inc. | -9.1 Million USD | 559.988% |
Natera, Inc. | -383.27 Million USD | 110.926% |
Aspira Women's Health Inc. | -16.49 Million USD | 353.932% |
Standard BioTools Inc. | -54.45 Million USD | 176.897% |
23andMe Holding Co. | -291.87 Million USD | 114.347% |
Castle Biosciences, Inc. | -45.02 Million USD | 193.008% |
Personalis, Inc. | -96.8 Million USD | 143.257% |
Aclaris Therapeutics, Inc. | -117.56 Million USD | 135.619% |
Applied DNA Sciences, Inc. | -9.59 Million USD | 536.616% |
OpGen, Inc. | -29.51 Million USD | 241.9% |
T2 Biosystems, Inc. | -43.87 Million USD | 195.444% |
Myriad Genetics, Inc. | -67.8 Million USD | 161.764% |
ICON Public Limited Company | 1.63 Billion USD | 97.434% |
NeoGenomics, Inc. | -17.6 Million USD | 337.837% |
Star Equity Holdings, Inc. | -1.68 Million USD | 2582.276% |
IDEXX Laboratories, Inc. | 1.21 Billion USD | 96.561% |
RadNet, Inc. | 292.78 Million USD | 85.697% |
MDxHealth SA | -30.46 Million USD | 237.443% |
Psychemedics Corporation | -251 Thousand USD | 16783.665% |
Illumina, Inc. | -608 Million USD | 106.888% |
Check-Cap Ltd. | -17.64 Million USD | 337.271% |
Twist Bioscience Corporation | -176.7 Million USD | 123.698% |
DarioHealth Corp. | -53.49 Million USD | 178.282% |
Fulgent Genetics, Inc. | -46.55 Million USD | 189.955% |
Sera Prognostics, Inc. | -35.28 Million USD | 218.673% |
ENDRA Life Sciences Inc. | -9.78 Million USD | 527.97% |
OPKO Health, Inc. | -65.51 Million USD | 163.917% |
Medpace Holdings, Inc. | 363.15 Million USD | 88.469% |
Neogen Corporation | 182.59 Million USD | 77.066% |
Intelligent Bio Solutions Inc. | -8.81 Million USD | 575.285% |
Prenetics Global Limited | -47.89 Million USD | 187.431% |
Mainz Biomed B.V. | -25.01 Million USD | 267.429% |
bioAffinity Technologies, Inc. | -7.62 Million USD | 648.884% |
Trinity Biotech plc | -24.09 Million USD | 273.774% |
Neuronetics, Inc. | -22.75 Million USD | 283.998% |
Sotera Health Company | 514.14 Million USD | 91.855% |
bioAffinity Technologies, Inc. | -7.62 Million USD | 648.884% |